Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 2

A 2026 review links rare peripheral nerve problems with rapid weight loss during semaglutide or tirzepatide treatment.

Two phase 3 trials support resmetirom and semaglutide in MASH, but their separate designs do not establish which treatment works better.

A cohort study linked semaglutide initiation to lower cigarette use among people with HIV, but it cannot show that the medicine caused the change.

A single tirzepatide case report links accidental intradermal injection with increased adverse events, but cannot measure the risk.

A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.

A new perspective uses semaglutide trial data to ask how adolescent GLP 1 care should track muscle, bone, and physical function.

A case report links severe restriction after sleeve gastrectomy, semaglutide, and tirzepatide with atypical anorexia nervosa.

A UK study of 8,127 women reported six-month outcomes from a structured digital programme where 99.8% started tirzepatide.

A study from ACHIEVE-3 shows what exit interviews can add to oral GLP-1 trial results, and what they cannot answer.

A 2026 meta-analysis found no cognitive or functional benefit from GLP-1 receptor agonists in Alzheimer's disease or mild cognitive impairment.

A source-led guide to the evidence, safety limits, and unanswered questions around GLP-1 and dual GIP/GLP-1 obesity medicines.

Tirzepatide weight loss trials recorded hair loss in 4% to 5% of participants, compared with 1% on placebo.